HSPA5 and neoplasm: The ability of PAT-SM6 to bind both GRP78 and LDL is consistent with the proposal that PAT-SM6 kills cells by delivering excess lipid in the form of LDL into tumours by binding simultaneously to GRP78 present on the surface of tumour cells [2].